Login / Signup

Treatment of Reactive Arthritis with Biological Agents.

Avarna AgarwalDebashis MaikapPrasanta Padhan
Published in: Current rheumatology reports (2024)
Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.
Keyphrases
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • ankylosing spondylitis
  • combination therapy
  • disease activity
  • electronic health record
  • artificial intelligence